We are live on ! Find out more
SL

Siren LLC Portfolio holdings

AUM $4.94B
1-Year Est. Return 244.43%
This Fund
S&P 500
This Quarter Est. Return
+34.74%
1 Year Est. Return
+244.43%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.94B
AUM Growth
+$1.33B
Cap. Flow
+$314M
Cap. Flow %
6.35%
Top 10 Hldgs %
44.63%
Holding
126
New
26
Increased
32
Reduced
21
Closed
9

Top Buys

Rank Stock Value
1
PBLS
Parabilis Medicines Inc
PBLS
+$82.7M
2
ABVX
Abivax
ABVX
+$65.2M
3
COAG
Hemab Therapeutics
COAG
+$57.6M
4
RLAY icon
Relay Therapeutics
RLAY
+$53M
5
KLRA
Kailera Therapeutics
KLRA
+$48.7M

Top Sells

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$60.4M
2
EWTX icon
Edgewise Therapeutics
EWTX
+$42.9M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$41.8M
4
RVMD icon
Revolution Medicines
RVMD
+$30.8M
5
KYMR icon
Kymera Therapeutics
KYMR
+$21.6M

Sector Composition

Rank Sector Weight
1 Healthcare 92.94%
2 Technology 3.57%
3 Communication Services 1.85%
4 Financials 0.87%
5 Consumer Discretionary 0.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IREN icon
76
Iris Energy
IREN
$17.1B
$8M 0.16%
175,000
+131,900
+306% +$6.86M
AMZN icon
77
Amazon
AMZN
$2.71T
$7.75M 0.16%
32,500
-14,141
-30% -$3.55M
CRWD icon
78
CrowdStrike
CRWD
$252B
$7.63M 0.15%
40,000
-52,280
-57% -$7.43M
DSGN icon
79
Design Therapeutics
DSGN
$802M
$7.57M 0.15%
+523,212
New +$6.52M
PDD icon
80
Pinduoduo
PDD
$111B
$7.25M 0.15%
95,000
+11,599
+14% +$1.07M
MSLE
81
Satellos Bioscience
MSLE
$203M
$6.94M 0.14%
892,074
– –
DT icon
82
Dynatrace
DT
$16.1B
$6.81M 0.14%
155,000
+5,000
+3% +$195K
AAPL icon
83
CALL
Apple
AAPL
$4.92T
$6.66M 0.13%
+23,000
New +$6.58M
TENX icon
84
Tenax Therapeutics
TENX
$69.6M
$6.21M 0.13%
427,141
– –
VTVT icon
85
vTv Therapeutics
VTVT
$124M
$6.14M 0.12%
163,000
– –
ELOX
86
Eloxx Pharmaceuticals
ELOX
$61.5M
$5.55M 0.11%
+400,000
New +$5.1M
AGMB
87
AgomAb Therapeutics NV
AGMB
$589M
$5.34M 0.11%
411,250
– –
BABA icon
88
Alibaba
BABA
$270B
$4.8M 0.1%
+50,000
New +$6.26M
KRRO icon
89
Korro Bio
KRRO
$174M
$4.58M 0.09%
347,718
– –
CLBT icon
90
Cellebrite
CLBT
$2.97B
$4.55M 0.09%
311,544
– –
IVVD icon
91
Invivyd
IVVD
$221M
$4.36M 0.09%
5,000,000
+1,000,000
+25% +$1.25M
OUST icon
92
Ouster
OUST
$2.52B
$4.22M 0.09%
+67,500
New +$2.27M
PALI icon
93
Palisade Bio
PALI
$298M
$4.18M 0.08%
+2,000,000
New +$3.94M
AEVA
94
Aeva Technologies
AEVA
$1.06B
$4.18M 0.08%
145,459
+35,459
+32% +$698K
SEER icon
95
Seer Inc
SEER
$106M
$4.08M 0.08%
2,458,673
– –
NBP
96
NovaBridge Biosciences American Depositary Shares
NBP
$190M
$3.91M 0.08%
2,004,739
-995,261
-33% -$2.03M
GTLB icon
97
GitLab
GTLB
$8.37B
$3.82M 0.08%
125,000
+25,000
+25% +$634K
ODTX
98
Odyssey Therapeutics
ODTX
$1.12B
$3.74M 0.08%
+200,000
New +$3.51M
FHTX icon
99
Foghorn Therapeutics
FHTX
$249M
$3.52M 0.07%
720,720
– –
AGEN
100
Agenus
AGEN
$325M
$3.26M 0.07%
1,064,250
– –
2 3
4
5 6

Similar funds

AAS
Ameritas Advisory Services Lincoln, Nebraska $4.96B AUM 27.52% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
FC
Freemont Capital Singapore $4.9B AUM 11.61% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $4.99B AUM 23.08% 1-Year Est. Return
CPIG
Chicago Partners Investment Group Chicago, Illinois $5B AUM 26.84% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $5B AUM 26.58% 1-Year Est. Return

Siren LLC's Q2 2026 Portfolio in Review

As of Q2 2026, Siren LLC held 126 positions worth $4.94B, up 37% from $3.61B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Siren LLC deployed $314M of net new capital in Q2 2026, opening 26 new positions and adding to 32 existing holdings. Its largest new stake was Parabilis Medicines Inc: 2,992,259 shares worth $81.9M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Scholar Rock, an estimated $60.4M trimmed.

  • Siren LLC's largest Q2 2026 buy was Parabilis Medicines Inc: 2,992,259 shares worth $81.9M.
  • Siren LLC added most to Enliven Therapeutics in Q2 2026, an estimated $43.7M increase.
  • Siren LLC's biggest Q2 2026 reduction was Scholar Rock, cutting an estimated $60.4M.
  • Siren LLC fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $41.8M.
  • Siren LLC's ten largest holdings make up 45% of its $4.94B portfolio in Q2 2026.
  • Siren LLC opened 26 new positions and closed 9 in Q2 2026.
  • Siren LLC's portfolio value rose 37% quarter-over-quarter to $4.94B.

Based on Siren LLC's 13F filing for Q2 2026, filed 13 Aug 2026.